Evaluation of the Novel XF Drugs as Bacterial Resistance Breakers

迫切需要新药来治疗由细菌引起的感染，这些细菌现在对目前市场上的许多抗生素都有抗药性。这是在低收入和中等收入国家(LMIC)遇到的一个全球性问题，在这些国家，医疗保健服务可能不那么普遍，因此影响更大。英国卫生与社会保障部(DHSc)和中国科技部(MOST)联合资助的抗微生物耐药性(AMR)产业研究项目旨在扩大围绕新型抗菌XF药物疗效的知识，以应对世界卫生组织(WHO)确定的、高优先级、多药耐药(MDR)的细菌病原体。该计划还将检查这些新药与现有的但基本上无效的抗生素的疗效。这项研究的积极数据可能会导致一系列新药的开发，这些新药的价格可能具有竞争力，从而使LMICs和中国的患者更容易获得负担得起的药物。

There is an urgent need for new drugs to treat infections resulting from bacteria that are now resistant to many of the current marketed antibiotics. This is a global issue encountered in low and middle-income countries (LMICs) where healthcare provisions may be less prevalent and so the impact is even greater. The jointly funded UK Department of Health and Social Care (DHSC) and Chinese Ministry of Science and Technology(MoST) Anti-Microbial Resistance (AMR) Industrial Research program aims to extend the knowledge surrounding the efficacy of novel anti-bacterial XF drugs to tackle World Health Organisation (WHO)-identified, high priority, multi-drug resistant (MDR) bacterial pathogens. The program will also examine the efficacy of these novel drugs in combination with existing, but largely ineffective antibiotics. Positive data from this study could lead to the development of a range of new medicines that could be competitively priced so as to permit patients from LMICs and China greater access to affordable medication.